Trial record 2 of 27 for:    stem cells AND cerebral palsy

Safety and Efficacy of Bone Marrow Derived Autologous Cells Treatment of Cerebral Palsy in Subjects Above 15 Years (BMACCP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2014 by Chaitanya Hospital, Pune.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Dr. Sachin Jamadar, Chaitanya Hospital, Pune
ClinicalTrials.gov Identifier:
NCT01834664
First received: April 8, 2013
Last updated: September 16, 2014
Last verified: September 2014
  Purpose
This Study is Single arm, Single Centre trial to study the safety and efficacy of bone marrow derived autologous mononuclear cells (100 millions per dose)study enrollment duration 36 months sample size 100 patients should be treated (above 15 years of age) with cerebral palsy in India. Primary outcome measures are improvement in walking ability and kinetic gait pattern.

Condition Intervention Phase
Ataxic Infantile Cerebral Palsy
Biological: stem cell (MNCs )
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Cerebral Palsy in Subjects Above Years (BMACCP) .It is Self Funded (Patients' Own Funding) Clinical Trial

Resource links provided by NLM:


Further study details as provided by Chaitanya Hospital, Pune:

Primary Outcome Measures:
  • Improvement in muscle rigidity using Ash worth scale [ Time Frame: 6 Months ]

Secondary Outcome Measures:
  • Improvement in dysregulated phospholipid Metabolism [ Time Frame: 6 months ]
  • Improvement in walking ability and kinetic gait Pattern [ Time Frame: 6 Months ]
  • Improvement in overall motor control using oxford scale [ Time Frame: 6 Months ]
  • Improvement in orbitoFrontal-amygdala circuit and self-regulation of social -emotional behaviour [ Time Frame: 6 month ]
  • Improvement in motor-linked implicit learning [ Time Frame: 6 month ]

Estimated Enrollment: 100
Study Start Date: March 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
STEM CELL
Transfer of autologous stem cell [MNCs ]intrathecally
Biological: stem cell (MNCs )
Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
Other Name: Intra thecal autologous stem cell MNCs

Detailed Description:
Cerebral Palsy is commonest cause of Disability in India and south East Asia. This Study is devised to quantify the safety and efficacy of bone marrow derived autologous mononuclear cells(100 millions per dose)study enrolment duration 36 months sample size 100 patients should be treated (above 15 years of age) with cerebral palsy, in India. Primary outcome measures are improvement in walking ability and kinetic gait pattern as per as various clinical scales and also changes in the brain.
  Eligibility

Ages Eligible for Study:   15 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject aged above 15 years with a diagnosis of Cerebral Palsy. Regional Nerve damage as shown by Magnetic Resonance Imaging(MRI)
  • Patient suffer from cerebral palsy due to prenatal and postnatal cause,
  • Willing to undergoing Bone Marrow derived autologous stem cell therapy.
  • Able to Comprehend and give written informed consent form for the study
  • willing to come to the hospital for follow up visits as per the protocol requirements

Exclusion Criteria:

  • History of meningitis,meningoencephalitis , epilepsy or life threatening allergic or immune -mediated reaction
  • Hemodynamically unstable patients
  • history of or concurrent autoimmune disease or acute episode if Guillain- barre syndrome
  • peripheral Muscular dystrophy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01834664

Locations
India
Chaitanya Hospital
Pune, Maharashtra, India, 411009
Sponsors and Collaborators
Chaitanya Hospital, Pune
Investigators
Principal Investigator: ANANT E BAGUL, M.S CHAITANYA HOSPITAL
  More Information

Responsible Party: Dr. Sachin Jamadar, CO-Investigator, Chaitanya Hospital, Pune
ClinicalTrials.gov Identifier: NCT01834664     History of Changes
Other Study ID Numbers: 00109 
Study First Received: April 8, 2013
Last Updated: September 16, 2014

Keywords provided by Chaitanya Hospital, Pune:
Ataxic Infantile Cerebral Palsy stem cell therapy

Additional relevant MeSH terms:
Paralysis
Cerebral Palsy
Brain Damage, Chronic
Brain Diseases
Ataxia
Genetic Diseases, Inborn
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Diseases
Dyskinesias

ClinicalTrials.gov processed this record on January 19, 2017